Journal
CNS SPECTRUMS
Volume 25, Issue 3, Pages 343-351Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S109285291900083X
Keywords
Dopamine D(3)receptors; cariprazine; antipsychotic drugs; schizophrenia; negative symptoms; cognitive deficits
Categories
Ask authors/readers for more resources
Cariprazine is a new atypical antipsychotic drug (APD) with a unique pharmacodynamic profile, different from both typical and atypical APDs. Specifically, cariprazine acts as a partial agonist at the dopamine (DA) D(2)and D(3)receptors and serotonin 5-HT(1A)receptors, and as an antagonist at the 5-HT(2B)receptors. Moreover, it shows moderate affinities for adrenergic, histaminergic, and cholinergic receptors that are involved in mediating the side effects characteristic of typical APDs. In this review, we discuss the contribution of DA D(3)receptors (D(3)Rs) in the etiology and pathophysiology of schizophrenia and the potential benefits that may be associated with a more selective targeting of D3R by APDs, as compared to other dopaminergic and non-dopaminergic receptor subtypes. Cariprazine, by acting on D(3)Rs, ameliorates anhedonia and cognitive deficits in animal models based on environmental or pharmacological manipulation. The reviewed results support the potential benefits of cariprazine in treating negative symptoms and cognitive deficits of schizophrenia, and therefore representing a promising approach in addressing the unmet clinical needs for the improved treatment of this serious neuropsychiatric disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available